# A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

> **NCT02555878** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 841 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02555878
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2018-08-24
- **Final completion:** 2018-08-24
- **Target enrollment:** 841 (ACTUAL)
- **Last updated:** 2019-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02555878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02555878, "A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02555878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*